FOLLOW US

Oncology-focused biopharmaceutical firm Eikon Therapeutics stepped onto the public stage Thursday, as Eikon's Upsized $381M IPO powered its Nasdaq debut in a show of investor confidence and late-stage biotech ambition.

The company raised $381 million after selling 21.2 million shares at $18 each. Trading began under the ticker symbol EIKN, marking a milestone moment for the cancer drug developer as it transitions from privately backed innovator to publicly traded contender.

From $300M Target to $381M Reality

Just a week earlier, Eikon had signaled to regulators that it intended to raise about $300 million by offering 17.6 million shares priced between $16 and $18.

But demand proved stronger than anticipated. The company increased both the size and scale of the deal, pricing at the top of the marketed range and expanding the share count — a clear sign that Wall Street’s appetite for oncology innovation remains robust.

The offering is expected to close Friday. Additionally, Eikon granted its underwriters a 30-day option to purchase up to roughly 3.2 million additional shares of common stock at the IPO price, potentially pushing the total raise even higher.

Legal Teams Behind the Deal

Covington & Burling LLP advised Eikon in the transaction, with a team that included Brian Rosenzweig, Bradley Chernin and Brianna Bloodgood.

Davis Polk & Wardwell LLP represented the underwriters, led by Alan Denenberg and Emily Roberts.

Building the Next Generation of Cancer Medicines

According to filings with the U.S. Securities and Exchange Commission, Eikon is a late-stage clinical biopharmaceutical company advancing a pipeline of oncology drug candidates aimed at areas of significant unmet medical need. The therapies under development could ultimately become foundational treatments in cancer care.

The company also leverages its proprietary technology platform to design internally developed, novel therapies — blending scientific research with engineering precision.

“Our vision is to become a generational leader, by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster,” Eikon stated in its SEC filing. “We believe our product candidates reflect strong scientific and clinical potential and could eventually become critical medicines in the treatment paradigm of various cancers.”

Eikon counts prominent venture capital firms among its backers, including Lux, Foresite Capital and The Column Group — a trio known for betting early on high-risk, high-reward biotech ventures.

Biotech Momentum Continues

Eikon’s market entrance comes amid a flurry of biotech activity. Just one day earlier, hair loss drug developer Veradermics Inc. launched its own public debut after raising $256 million in an upsized offering.

Veradermics sold 15.1 million shares at $17 apiece — above its marketed range of $14 to $16 — after previously announcing plans to offer nearly 13.4 million shares. The company began trading Wednesday on the New York Stock Exchange.

Together, the back-to-back listings signal renewed energy in biotech capital markets, where innovation and investor optimism are once again converging.

With Eikon's Upsized $381M IPO now etched into Nasdaq’s trading history, the company begins its next chapter — one measured not only in share prices, but in clinical milestones and the promise of new cancer therapies.